Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Sun Pharmaceutical Industries
Sun Pharmaceutical Industries
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Drug Delivery
Sun Pharma enters definitive financial agreement with Concert
Concert stockholders will also receive a tradable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share of common stock in cash
Ingredients
Sun Pharma questions pandemic effects on business
Director has said performance reflects the impact of the global COVID-19 pandemic but vertical integration has benefitted supply chain for formulations
Finance
Sun Pharma licenses seven generics to Chinese company
China Medical System Holdings subsidiary will develop and commercialise the Indian company's seven generic products for Mainland China
Finance
Sun Pharma to operate manufacturing plants in Japan
India's drugmaker taps into dermatology market with acquisition of Japan-based Pola Pharma
Pharmaceutical
Sun Pharma opens new cGMP production line in India
The Mumbai-based company has installed a production line in Guwahati to enhance the manufacturing capacity of sterile products
Regulatory filing of tildrakizumab in Europe
Potential of tildrakizumab for patients with moderate-to-severe plaque psoriasis, without burden of frequent injections
Finance
Almirall pays Sun Pharma $50 million upfront in licensing deal for psoriasis treatment in Europe
Phase III clinical trials of tildrakizumab were completed in May, with positive results
Subscribe now